• Stevanato Group to showcase the benefits of an integrated solutions approach at CPhI Worldwide Conference, November 9-11

    Spotlight on the development of proprietary devices like the SG Alina pen injector platform

    Piombino Dese (PD), Italy, November 4, 2021 – Stevanato Group, a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, will showcase the benefits of its integrated solutions approach at CPhI Worldwide, November 9-11, 2021. The company will be exhibiting at Fiera Milano in Milan – in the InnoPack zone in Hall 6, Booth #G20.

  • Owen Mumford launches new Aidaptus auto-injector

    News: 

    Aidaptus is a two-step, spring-powered, single use auto-injector with a design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.

    Aidaptus has a patient-centric design with automatic needle insertion that provides a simple and consistent user experience. The stopper sensing technology, coupled with the independent, two-phase needle insertion and drug delivery, reduces any impact forces on the syringe, mitigating the risk of syringe breakages during use. With a needle that is shielded before, during and after use, Aidaptus provides reassurance to users who are new to auto-injectors as well as those who experience needle phobia. It can also give users confidence that the injection has been successfully completed with an audible notification at the start and end of the procedure. In addition, a bright yellow plunger rod is visible though a large window in the device confirming the end of injection.

    Aidaptus is available in two base platform options: a clear outer body with colour overwrap permitting rapid selection of window size or traditional opaque housing, offering versatility for both branding and customisation as well as options for market segmentation and life cycle management. Its highly compact nature reflects the excellence in sustainable design and human factors engineering used throughout its development; coupled with consideration for ease of final assembly through application of design for manufacture (DfM) principles.

    Michael Earl, director, Owen Mumford Pharmaceutical Services, said: “Our Aidaptus auto-injector platform has been designed to facilitate the growing market for subcutaneous injections used to treat a variety of chronic diseases like rheumatoid arthritis, Crohns’ disease and multiple sclerosis. With the increasing move towards treatment outside of the acute care setting, Aidaptus will help patients to self-administer their individual therapies using a simple and easy to use device. At the same time, this auto-injector can help to reduce complexity and risk in supply chain and final assembly for pharmaceutical and biotechnology companies’ combination products thanks to its ability to adapt to different syringe sizes and fill volumes. It is often the case that during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now the device does not have to be changed as well.”

    Aidaptus has been designed to meet the challenges of changes to drug formulation or injected volume and can therefore help reduce risk during drug development and lifecycle management.

  • Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve® Nasal Naloxone Treatment

    News: 

    Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions and Noble, an Aptar Pharma company, world leader in drug delivery training device programs, today announced their collaboration with dne pharma, a leader in addiction medicine in Northern Europe.

    Using Aptar Pharma’s patented Unidose Liquid System, Ventizolve® is a ready-to-use rescue treatment that can quickly reverse the life-threatening effects of an opioid overdose. Noble’s Unidose trainer kit, which replicates Aptar’s Unidose device, will be used by dne pharma as part of a broad patient onboarding and awareness program for Ventizolve® in outreach and drug treatment centers across the Nordics – the first trainer kit of its kind for a naloxone nasal drug product launch.

    According to The World Health Organization (WHO), opioids and opioid overdose account for more than 70% of the half a million drug-use related deaths that are reported annually worldwide. In their Opioid Task Force 2020 Progress Report, the American Medical Association (AMA) states that a “continuing increase in drug overdoses is fueling the evolution of a more dangerous and complicated epidemic”, and urges stakeholders to come together to work collaboratively on meaningful action to remove barriers and increase patient access to evidence-based care, both to save lives and help end the epidemic.

    Dne pharma’s focus is on improving existing treatments within addiction therapy. Nina Måsvær, Marketing Manager at dne pharma explains, “With the growing opioid overdose epidemic, we were fortunate to collaborate with Professor Ola Dale at the Norwegian University of Science and Technology in Trondheim on the development of a nasal naloxone sprayer for pre-hospital and take-home use and were able to secure final use approval for Ventizolve® in 12 European countries in 2018.”

    Nasally Administered Opioid Overdose Rescue Treatment

    Aptar Pharma’s Unidose Liquid System is the drug delivery device used to administer Ventizolve® and is a ready-to-use, one-step nasal device designed to enable the delivery of a precise, single dose quickly, easily and reliably, and without the need for administration by a trained professional.

    “With over 100 million devices sold worldwide, our patented Unidose Technology Platforms are approved by the U.S. FDA and European regulatory authorities for a wide range of treatments from chronic conditions such as migraine and vitamin B12 deficiency to life-saving drugs that counter an opioid overdose,” commented Isabelle Menard, Director of Strategy and Business Integration at Aptar Pharma.

    Noble is providing the training and onboarding component with its Unidose training device that replicates the form and function of Aptar Pharma’s Unidose drug delivery device. The Unidose training device features a novel twist reset function, making it easier for users and caregivers to practice administering a dose quickly and effectively so that they are ready when confronted with an emergency situation.

    “We’re honored to provide the training support for this important initiative to combat the growing opioid overdose epidemic,” added Joe Masci, Noble’s Executive Director of Business Development. “The levels of anxiety that come with using a drug delivery device can be high under normal circumstances, let alone under stress and using a product you are not familiar with. When faced with an emergency situation, users need to have the confidence to come to someone’s aid.”

    Drug Repurposing to Nasal Drug Delivery

    Dne pharma is among a new generation of industry disruptors who are making their mark by repurposing existing therapies for nasal drug delivery, with benefits such as better patient convenience, greater personal empowerment, improved user compliance, and in some cases, overcoming objections to more invasive delivery routes. More importantly, in the case of a rescue treatment, the recipient does not need a healthcare professional (HCP) to administer the drug, which could be life-critical in an emergency situation where, for example, the patient is unconscious.

    “Aptar Pharma’s expertise in drug repurposing using nasal delivery solutions, combined with Noble’s innovative training and onboarding platform, make them the perfect partners to support us in bringing this life-saving drug product to market,” concluded Nina Måsvær, dne pharma.

  • Aptar Declares Quarterly Dividend

    Crystal Lake, Illinois, October 15, 2020 - AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active packaging solutions, today declared a
    quarterly cash dividend of $0.36 per share. The payment date is November 18, 2020, to stockholders of record as of October 28, 2020.